Home>>Signaling Pathways>> Metabolism>> Factor Xa>>Otamixaban

Otamixaban Sale

(Synonyms: 奥米沙班; FXV673) 目录号 : GC17726

Otamixaban(FXV673) 是一种有效的 (Ki = 0.5 nM)、选择性、快速作用、竞争性和可逆的 fXa 抑制剂,可有效抑制游离和凝血酶原结合的 fXa。

Otamixaban Chemical Structure

Cas No.:193153-04-7

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥2,673.00
现货
5mg
¥2,430.00
现货
10mg
¥3,780.00
现货
25mg
¥7,200.00
现货
50mg
¥10,800.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

实验参考方法

Vitro experiment [1]:

Samples

plasma derived from humans, primates, dogs, rabbits and rats

Preparation method

The solubility of this compound in DMSO is >22.4mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months.

Reacting condition

100 ng/mL

Applications

The anticoagulant effect of Otamixaban in plasma was rabbit>human>monkey>rat>dog. Humans were approximately 2.5 fold more sensitive to otamixaban than dogs in both the PT and aPTT assays. 100 ng/mL would be the effective plasma concentration to target for human clinical studies.

Animal experiment [1]:

Animal models

rat model of ferrous chloride-induced arterial thrombosis

Dosage form

50 μg/kg bolus and 5 μg/kg/min i.v. maintenance infusion

Application

In rat model of ferrous chloride-induced arterial thrombosis, Otamixaban exhibited a dose-dependent increase in time to occlusion with a maximal effective dose at about 50 μg/kg bolus and 5 μg/kg/min i.v. maintenance infusion. Compared to control, this dose caused a 40% reduction in thrombus mass.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

References:

[1] Guertin KR1, Choi YM. The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development. Curr Med Chem. 2007;14(23):2471-81.

产品描述

Otamixaban (FXV673) is a potent, selective, rapid acting, competitive and reversible inhibitor of factor Xa with IC50 value of 0.4 nM.[5]
Factor Xa is a serine endopeptidase which is activated into factor Xa by both factor IX with its cofactor, factor VIII known as intrinsic Xase, and factor VII with its cofactor, tissue factor. Factor Xa (fXa) is a pivotal serine protease situated at the juncture of the intrinsic and extrinsic pathways of the blood coagulation cascade.[2] Its singular role in thrombin activation and potentiating effects on clot formation makes it as a target for therapeutic intervention. FXa is responsible for the initiation of the coagulation cascade,[3] cleaving prothrombin to its active form thrombin, which then acts to convert soluble fibrinogen to insoluble fibrin and to activate platelets. Stabilization of the platelet aggregation by fibrin mesh ultimately leads to clot formation.[4] Thus, the inhibition of fXa (in the physiologically relevant prothrombinase complex) represents an attractive target for the development of novel antithrombotic agents.[5]
Otamixaban (FXV673) selectively and competitively inhibit FXa, suppressing prothrombin activity at the sites of blood clot (thrombus) formation. This leads to a decrease in blood clot formation in a dose dependent manner.[1] Reducing blood clot formation will decrease blood flow blockages, thus possibly lowering the risk of myocardial infarction, unstable angina, venous thrombosis, and ischemic stroke.[6] In conclusion, FXV673 is an effective inhibitor of fXa in the physiologically relevant human prothrombinase complex. Recently a new series of specific, direct acting inhibitors of Factor Xa has been developed. And they may be more effective against Factor Xa in that they inhibit both free Factor Xa and Factor Xa in the prothrombinase complex.[7]
References:
1.K. R. Guertin et al. Optimization of the-Aminoester Class of Factor Xa Inhibitors.Part 2: Identification of FXV673 as a Potent and Selective Inhibitor with Excellent In Vivo Anticoagulant Activity. Bioorg. Med. Chem. Lett. 12 (2002) 1671–1674.
2.Meyer-Michel Samama. et al. Monitoring plasma levels of factor Xa inhibitors: how, why and when? Expert Rev. Hematol.2013, 6(2), 155-164.
3.Rebello SS1. et al. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis. Br J Pharmacol. 2001 Aug;133(7):1190-8.
4.Valeria Chu. et al. Pharmacological Characterization of a Novel Factor Xa Inhibitor, FXV673. Thrombosis Research 103 (2001) 309–324.
5.Katsung, B., S. Masters and A. Trevor. Basic and Clinical Pharmacology 11th Edition. United States of America: McGraw-Hill, 2009.
6.Rebello SS1. et al. Role of short-term inhibition of factor Xa by FXV673 in arterial passivation: a study in a chronic model of thrombosis in conscious dogs. J Cardiovasc Pharmacol. 2001,38(2):288-97.
7.Turpie AG. "Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases". Arterioscler Thromb Vasc Biol,2007,27 (6): 1238-47.

Chemical Properties

Cas No. 193153-04-7 SDF
别名 奥米沙班; FXV673
化学名 methyl (2R,3R)-2-[(3-carbamimidoylphenyl)methyl]-3-[[4-(1-oxidopyridin-1-ium-4-yl)benzoyl]amino]butanoate
Canonical SMILES CC(C(CC1=CC=CC(=C1)C(=N)N)C(=O)OC)NC(=O)C2=CC=C(C=C2)C3=CC=[N+](C=C3)[O-]
分子式 C25H26N4O4 分子量 446.53
溶解度 ≥ 22.35 mg/mL in DMSO, ≥ 55 mg/mL in EtOH with gentle warming 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.2395 mL 11.1975 mL 22.3949 mL
5 mM 0.4479 mL 2.2395 mL 4.479 mL
10 mM 0.2239 mL 1.1197 mL 2.2395 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置